Amendments to the Specification:

Please replace the first page of the specification. A substitute first page is enclosed which includes a page number at the top of the page.

Please replace the paragraph [0019] beginning at page 5, with the following amended paragraph [0019]:

[0019] In the neoadjuvant treatment of inflammatory or T3 to T4 breast cancer, the diphenyl compound preferably is used in an amount of about 3 to about 10 mg/kg of patient, administered intravenously over a period of about 30 to about 90 minutes prior to administration of the chemotherapeutic agents and continuing for the period of administration of the chemotherapy agent. In the specific Phase II clinical trial described herein, there was employed 6 mg/kg of DPPE in the form of its hydrochloride salt, administered intravenously as an aqueous solution thereof over 80 minutes, with the last twenty minutes being accompanied by infusion of the chemotherapeutic agents, followed by the intravenous administration of an aqueous solution at a dose of 2.5 mg/kg of DPPE for 180 minutes accompanied by the infusion of ~~Taxol~~ Taxol® or for 60 minutes accompanied by the infusion of ~~Taxotere~~ Taxotere®.

Please replace the paragraph [0020] beginning at page 6, with the following amended paragraph [0020]:

[0020] A second regimen for ~~DPPE/Taxotere~~ DPPE/Taxotere® treatment is the intravenous administration of an aqueous solution of DPPE for 80 minutes, with the last 20 minutes being accompanied by infusion of the ~~Taxotere~~ Taxotere®, followed by infusion of ~~Taxotere~~ Taxotere® alone for 40 minutes.

Please replace the paragraph [0021] beginning at page 6, with the following amended paragraph [0021]:

[0021] The chemotherapy agents which are employed herein preferably are used in a total amount of 75 to about 225 mg/M^2 of patient consistent with the identity of the chemotherapy agent. The chemotherapeutic agents may be administered in an amount of about 50 to about 60 mg/M^2 of patient for doxorubicin or epirubicin, about 175 to about 225 mg/M^2 of ~~Taxol~~ Taxol® and about 75 to about 100 mg/M^2 of ~~Taxotere~~ Taxotere®. In the specific Phase II clinical trial described herein, there was employed 50 mg/M^2 of doxorubicin or epirubicin, and 175 mg/M^2 of ~~Taxol~~ Taxol® or 75 mg/M^2 of ~~Taxotere~~ Taxotere®, administered over the last 20 minutes of infusion of the DPPE solution and over a further 180 minutes for ~~Taxol~~ Taxol® or 60 minutes for ~~Taxotere~~ Taxotere®, accompanied by infusion of a 2.5 mg/kg of DPPE solution.

Please replace the paragraph [0023] beginning at page 6, with the following amended paragraph [0023]:

[0023] As set forth herein, a Phase II clinical trial was conducted on patients having inflammatory or T3 to T4 breast cancer in which patients were administered DPPE followed by doxorubicin or epirubicin and ~~Taxol~~ Taxol® or ~~Taxotere~~ Taxotere®. Various data from the clinical trial were collected and analyzed.

Please replace the paragraph [0024] beginning at page 7, with the following amended paragraph [0024]:

[0024] The results of this trial showed that DPPE along with doxorubicin/epirubicin and ~~Taxol/Taxotere~~ Taxol®/Taxotere® was an effective neoadjuvant treatment which lead to long term survival post surgery.

Please replace the paragraph [0026] beginning at page 7, with the following amended paragraph [0026]:

[0026] A Phase II clinical trial was carried out in which patients (N=8) with inflammatory (N=7) and T3 to T4 (N=1) breast cancer were treated with a combination of DPPE and epirubicin (EPI)/~~Taxol~~ Taxol® (N=5), a combination of DPPE and doxorubicin (DOX)/~~Taxol~~ Taxol® (N=2) and DPPE and a combination of DPPE and epirubicin/~~Taxotere~~ Taxotere® (N=1). DPPE was administered at a dose of 6 mg/M^2 over 80 minutes with a combination of epirubicin or doxorubicin at a dose of 50 mg/M^2 and ~~Taxol~~ Taxol® at a dose of 175 mg/M^2 or ~~Taxotere~~

Taxotere® at a dose of 75 mg/M^2 over the last 20 minutes and during a further 180 minutes for ~~Taxol~~ Taxol® or 60 minutes for ~~Taxotere~~ Taxotere®, at a dose of 2.5 mg/kg. The treatment was repeated at 21 day intervals for 6 cycles. The eight patients with inflammatory or T3 to T4 breast cancer had no previous chemo- or radiotherapy. When the chemotherapy cycles were complete, the cancerous tissue was removed and the patients observed.

Please replace the paragraph [0028] beginning at page 7, with the following amended paragraph [0028]:

[0028] These findings are compatible with the hypothesis advanced in copending United States Applications Nos. 60/331,242 filed November 9, 2001 and ~~_____~~ 10/494,961 filed ~~_____~~ January 3, 2005, the disclosures of which are incorporated herein by reference (~~WO _____~~) (WO03/039526), in the names of Lorne Brandes and Mark Vincent, that DPPE-based chemotherapy may preferentially target high-grade malignant cell populations.